International Journal of Cardiology and Cardiovascular Diseases

Original Research Open Access

Studies of NT-proBNP testing in the emergency department and evaluation of point of care testing for NT-proBNP using the LumiraDx instrument

Morgan Lundgren , David Smekal , Mats Eriksson , Anders Larsson

Presently, more than 10% of patients >70 years of age suffer from heart failure (HF). As the older population increases in numbers and also as a share of the total population, the prevalence of HF will increase [1,2]. Untreated, approximately 60-70% of these patients will die within 5 years [3,4].

Int J Cardiol Cardiovasc Dis, 2025, Volume 5, Issue 1, p1-5 | DOI: 10.46439/cardiology.5.029

Commentary Open Access

Should the cardiac heart valve prosthesis type choice also consider the valve size at the intraoperatively? Commentary on recent researches about sequential valve-in-valve

Caio Cesar Cardoso

Nowadays, there are two heart valve prosthesis types available: mechanical or biological. Apart from the long-term durability of mechanical heart valves, there are considerable advantages of bioprothesis, specifically regarding biocompatibility and the abdication of oral anticoagulation by warfarin, with the respective drawbacks and risks. A practical proof of this is that is estimated in the United States, between 2007 and 2011, 63.6% of prosthetic valve devices were made of bovine pericardium (an increase of 100% compared to the period from 1998 to 2001) [1,2].

Int J Cardiol Cardiovasc Dis, 2025, Volume 5, Issue 1, p6-8 | DOI: 10.46439/cardiology.5.29

Systematic Review Open Access

Prophylactic use of ACEIs, ARBs and BBs in anthracycline and trastuzumab induced cardiotoxicity in adult cancer patients: A systematic review

Sumana Kundu , Maryam Farhan Baloch , Josephine Ria Pitasari , Bijay Mukesh Jeswani , Yashvi Pethani , Sukhmandeep Singh Benipal , Abhishek Prasad

Cancer therapy related cardiac dysfunction (CTRCD) poses a significant challenge to the treatment of cancer patients receiving cardiotoxic chemotherapeutic regimen like anthracyclines and human epidermal growth factor receptor 2 (HER2) inhibitors like trastuzumab. This systematic review evaluated the efficacy and safety of conventional heart failure medications—angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs)—in preventing CTRCD in adults undergoing such therapies.

Int J Cardiol Cardiovasc Dis, 2025, Volume 5, Issue 1, p9-19 | DOI: 10.46439/cardiology.5.030